ANTI-TUMOR NECROSIS FACTOR ALPHA FOR RETINAL DISEASES: CURRENT KNOWLEDGE AND FUTURE CONCEPTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MIRSHAHI ALIREZA; HOEHN RENE; LORENZ KATRIN; KRAMANN CHRISTINA; BAATZ HOLGER

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Journal of Ophthalmic and Vision Research Year:2012 | Volume:7 | Issue:1 Page(s): 39-44

Download Full-Text

View:

300

Download:

144

Cites:

Information Journal Paper

Title

ANTI-TUMOR NECROSIS FACTOR ALPHA FOR RETINAL DISEASES: CURRENT KNOWLEDGE AND FUTURE CONCEPTS

Author(s)

Keywords

TUMOR NECROSIS FACTOR

TNF-α

AGE-RELATED MACULAR DEGENERATION

DIABETIC MACULAR EDEMA

UVEITIS

RETINAL VEIN OCCLUSION

Abstract

TUMOR NECROSIS FACTOR alpha (TNF-a) is a pro-inflammatory cytokine produced by macrophages and T-cells. It plays an important role both in inflammation and apoptosis. In the eye, TNF-a appears to have a role in the pathogenesis of inflammatory, edematous, neovascular and neurodegenerative disorders. Several TNF-blocking drugs have been developed and approved, and are in clinical use for inflammatory diseases such as rheumatoid arthritis, psoriasis and ankylosing spondylitis. TNF-a blockers are widely used in ophthalmology as an off-label alternative to “traditional”immunosuppressive and immune-modulatory treatments in noninfectious UVEITIS.Preliminary studies suggest a positive effect of intravenously administered TNF-a blockers, mainly infliximab, for treating refractory DIABETIC MACULAR EDEMA and neovascular AGE-RELATED MACULAR DEGENERATION. Unfortunately, much of the current data raises considerable safety concerns for intravitreal use of TNF-a inhibitors, in particular, intraocular inflammatory responses have been reported after intravitreal injection of infliximab. Results of dose-finding studies and humanized antibody or antibody fragments (e.g. adalimumab) are anticipated in the coming years; these will shed light on potential benefits and risks of local and systemic TNF-a blockers used for treatment of diseases of the retina and choroid.

Cites

No record.

References

No record.

Cite

APA: Copy

MIRSHAHI, ALIREZA, HOEHN, RENE, LORENZ, KATRIN, KRAMANN, CHRISTINA, & BAATZ, HOLGER. (2012). ANTI-TUMOR NECROSIS FACTOR ALPHA FOR RETINAL DISEASES: CURRENT KNOWLEDGE AND FUTURE CONCEPTS. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 7(1), 39-44. SID. https://sid.ir/paper/311485/en

Vancouver: Copy

MIRSHAHI ALIREZA, HOEHN RENE, LORENZ KATRIN, KRAMANN CHRISTINA, BAATZ HOLGER. ANTI-TUMOR NECROSIS FACTOR ALPHA FOR RETINAL DISEASES: CURRENT KNOWLEDGE AND FUTURE CONCEPTS. JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2012;7(1):39-44. Available from: https://sid.ir/paper/311485/en

IEEE: Copy

ALIREZA MIRSHAHI, RENE HOEHN, KATRIN LORENZ, CHRISTINA KRAMANN, and HOLGER BAATZ, “ANTI-TUMOR NECROSIS FACTOR ALPHA FOR RETINAL DISEASES: CURRENT KNOWLEDGE AND FUTURE CONCEPTS,” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 7, no. 1, pp. 39–44, 2012, [Online]. Available: https://sid.ir/paper/311485/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops